seid ihr wirklich sicher dass man hier einsteigen kann,wieso ist die aktie denn am tag der mexico news um 6% gefallen,da stimmt doch was nicht und das rieche nicht nur ich,das sagt motley fool zu ocugen
Ocugen
The fourth and final ultra-popular stock to avoid like the plague is small-cap biotech stock Ocugen ( OCGN -2.44% ).
Like Moderna, Ocugen's claim to fame is its ties to a COVID-19 vaccine. Ocugen has the commercialization rights to Bharat Biotech's Covaxin in the U.S. and Canada. In a 25,800-person clinical study in India, Covaxin produced a 78% vaccine efficacy. Considering how many people still need their initial inoculations in emerging markets, Covaxin is one of many promising global vaccines.
However, Ocugen is staring down multiple red flags. To begin with, most adults in the U.S. and Canada have already had their initial COVID-19 inoculations. Both countries have also invested heavily in these initial doses and booster shots. There simply may not be a market for a vaccine that, frankly, delivered lower vaccine efficacy than what Moderna and Pfizer/BioNTech can offer.
Furthermore, the U.S. Food and Drug Administration denied Ocugen's request to approve Covaxin on an emergency-use basis for adolescents, and has placed a temporary hold on the company's phase 2/3 study involving Covaxin.
With more effective vaccines already available, and Ocugen only able to make revenue from Covaxin in the U.S. and Canada, the company's window of opportunity to generate sales from COVID-19 looks to be almost fully closed.
Fazit: Finger wech,es gibt deutlich besseres !!!!
|
Thread abonnieren
ETF-Sparplan